SCHEMBL20057547

SCHEMBL20057547

CNC(=O)Nc1ccc(NC(=N)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
CYP17A1 P05093 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPK14 Q16539 1/20 0.40
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RECQL P46063 1/20 0.39
PTPN11 Q06124 1/20 0.39
MAPKAPK2 P49137 1/20 0.38
PSMB8 P28062 1/20 0.38
NAMPT P43490 1/20 0.38
LMNA P02545 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
PRMT1 Q99873 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13017212 0.85 TDP1 (0.44) ALDH1A1CYP17A1KMT2APOLBPTPN11
SCHEMBL20057524 0.84 CYP17A1 (0.55) ALDH1A1CYP17A1KMT2AMAPK14POLB
SCHEMBL8385553 0.82 MAPT (0.48) ALDH1A1CYP17A1KMT2APOLBSMN1; SMN2
SCHEMBL2243542 0.80 CYP17A1 (0.46) CYP17A1MAPK14PTPN11NAMPT
SCHEMBL20057549 0.78 ALDH1A1 (0.42) ALDH1A1CYP17A1KMT2AMAPK14POLB
SCHEMBL8258345 0.75 NAMPT (0.59) ALDH1A1CYP17A1MAPK14SMN1; SMN2PTPN11
SCHEMBL17203045 0.75 ALDH1A1 (0.51) ALDH1A1KMT2APOLBSMN1; SMN2NR1H4
SCHEMBL8233731 0.75 TDP1 (0.36) KMT2AMEN1
SCHEMBL20332108 0.74 TSHR (0.49) ALDH1A1KMT2APOLBSMN1; SMN2LMNA
SCHEMBL8491406 0.73 CYP17A1 (0.51) CYP17A1MAPK14PTPN11MAPKAPK2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885CYP17A1 911/4885KMT2A 234/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885CYP17A1 911/4885KMT2A 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.